Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Non-Small-Cell Lung Cancer: early-phase trial registry
9 of 23 indexed Advanced Non-Small-Cell Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #724 of 28,707 conditions by registered trial count.
23 US clinical trials · 9 currently recruiting · #724 of 28,707 conditions by registered trial count
Advanced Non-Small-Cell Lung Cancer: 23 US clinical trials tracked, 9 recruiting.
Advanced Non-Small-Cell Lung Cancer is the subject of 23 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most active sponsor is Bayer, running 3 of these trials.
Enrollment posture brief
Registry condition advanced-non-small-cell-lung-cancer
OPEN 9 | RECR 39% | LATE 5 | EARLY 17 | RANK #724 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Metastatic Colorectal Cancer (39% recruiting · 46 trials)
Advanced Non-Small-Cell Lung Cancer lists 9 open slots (39% of 23 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Non-Small-Cell Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Non-Small-Cell Lung Cancer recruits in line with its size-band peers.
9 of 23 indexed trials (39.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Advanced Non-Small-Cell Lung Cancer trials is spread across many organizations.
Bayer accounts for 3 of 23 trials (13%). 14 distinct sponsors appear on at least one study for this condition label.
-
Typical Advanced Non-Small-Cell Lung Cancer enrolment sits around 310 participants.
Median target enrolment is 310 among the 23 trials that report a genuine target (sentinel values excluded). 7 of those (30.4%) plan for fewer than 100 participants.
-
Advanced Non-Small-Cell Lung Cancer research is mostly interventional.
22 interventional and 1 observational studies make up this index (95.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
23 total, page 1 of 1
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Pfizer
NCT07222566
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics
NCT04613596
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
ArriVent BioPharma
NCT07185997
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
NCT07090499
A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Bayer
NCT06452277
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT02133196
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
Virginia Commonwealth University
NCT06731413
Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT05777603
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
CellSight Technologies
NCT06107374
Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients
Regeneron Pharmaceuticals
NCT06269133
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals
NCT05785767
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
Mirati Therapeutics
NCT04685135
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
Gilead Sciences
NCT05676931
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
ArriVent BioPharma
NCT05607550
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
Bayer
NCT05099172
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
AstraZeneca
NCT02143466
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
ArriVent BioPharma
NCT05364073
The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer
Yale University
NCT04699123
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
Fujifilm Pharmaceuticals U.S.A.
NCT05318573
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
Regeneron Pharmaceuticals
NCT05557591
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
Bristol-Myers Squibb
NCT00633789
Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer
OSI Pharmaceuticals
NCT00072631
A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants
Bayer
NCT06378658
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 11 |
| Phase 3 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Non-Small-Cell Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Non-Small-Cell Lung Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Non-Small-Cell Lung Cancer page
23 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Advanced Non-Small-Cell Lung Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Bayer sponsors the most Advanced Non-Small-Cell Lung Cancer trials on record, review their full trial history before evaluating a specific study. See Bayer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Non-Small-Cell Lung Cancer condition card totals 23 registered trials; most-linked intervention Pembrolizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.